February 2024 in “The Journal of Sexual Medicine” 5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.
Dutasteride is more effective and better tolerated than finasteride for hair loss treatment.
November 2023 in “Bioorganic Chemistry” Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.
November 2023 in “Expert Opinion on Pharmacotherapy” Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
September 2023 in “Forum Dermatologicum” Various treatments for common hair loss in men and women are effective, but should be tailored to individual needs and potential side effects.
July 2023 in “Dermatology and Therapy” 5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.
June 2023 in “Journal of chemical metrology” A new method found unlisted drugs in two popular hair serums, posing a health risk.
June 2023 in “Brazilian Journal of Health Review” Common baldness is a hereditary condition that can be treated with medications or surgery to prevent progression and improve self-esteem.
May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
April 2023 in “Dermatologica Sinica” Sex hormones affect hair growth and loss, and treatments for related hair diseases include various medications, hair transplantation, and light therapy.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
October 2022 in “Revista Eletrônica Acervo Médico” 5-Alpha-Reductase Inhibitors can cause negative side effects.
Certain medications, especially 5-alpha reductase inhibitors, are commonly linked to erectile dysfunction.
April 2022 in “Medicina estética” Minoxidil is the only FDA-approved treatment for female hair loss, with other potential treatments needing more research for effectiveness.
The document suggests that drugs for prostate issues might cause lasting sexual, mental, and physical health problems due to blood vessel damage in the penis.
September 2021 in “Clinical research in dermatology” 5-Alpha-Reductase inhibitors might help slow down hair loss in Frontal Fibrosing Alopecia but are not a primary treatment and need more research.
July 2021 in “Belarusian State Pedagogical University repository (Belarusian State Pedagogical University)” PMC shows promise as a treatment for hair loss.
May 2021 in “The FASEB Journal” The research gives new understanding on how human steroid 5α-reductases work and how drugs like finasteride inhibit them, which could help in creating new drugs.
April 2021 in “Advances in Cosmetic Surgery” Hair restoration can be achieved through non-surgical treatments like minoxidil, antiandrogens, phototherapy, and PRP procedures, or through surgical methods like hair transplantation. Continued treatment is needed to maintain results, and full results are visible after 12-18 months.
January 2021 in “Faculty of 1000 Research Ltd” Phytochemicals may offer safer alternatives to synthetic drugs for prostate cancer treatment.
June 2020 in “Medicina estética” More research is needed to find effective treatments for Female Pattern Hair Loss.
June 2020 in “Medicina estética (Madrid)” Female pattern hair loss is common and should be treated early to prevent worsening, with Minoxidil being the main approved treatment.
March 2020 in “StatPearls” Medicines called 5-alpha-reductase inhibitors, like finasteride and dutasteride, are useful for treating enlarged prostate and male pattern hair loss.
August 2019 in “Key engineering materials” A microemulsion with Carthamus tinctorius extract effectively inhibits 5α-reductase and improves skin and hair follicle delivery.
May 2019 in “Australasian Journal of Dermatology” The conclusion is that managing hair loss conditions like FFA and melanoma requires individualized approaches, considering new findings and balancing treatment benefits with potential risks.
December 2018 in “Actas urológicas españolas” 5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.
January 2018 in “Surgical and Cosmetic Dermatology” 5-alpha reductase inhibitors like finasteride and dutasteride are effective for treating enlarged prostate and male pattern hair loss.
January 2018 in “Surgical and Cosmetic Dermatology” Finasteride and dutasteride are effective for male hair loss and enlarged prostate but may cause reversible sexual side effects.
May 2017 in “Psychiatric news” BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.
April 2017 in “Austin Journal of Cancer and Clinical Research” 5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.